Evidence map›Paper›PMID 40713763›Full record

ArticleCancer & metabolism2025

Pharmacological inhibition of Peroxisome Proliferation-Activated Receptor Delta (PPARδ) imparts selective leukemia cell death.

Yingying Yang, Ekaterina Parfenova, Nikolina Vrdoljak, Mark Minden, Jessica Luc, Andrew C Doxey, Paul A Spagnuolo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yingying YangDepartment of Food Science, University of Guelph, 50 Stone Rd., Guelph, ON, N1G2W1, Canada.
Ekaterina ParfenovaDepartment of Food Science, University of Guelph, 50 Stone Rd., Guelph, ON, N1G2W1, Canada.
Nikolina VrdoljakDepartment of Food Science, University of Guelph, 50 Stone Rd., Guelph, ON, N1G2W1, Canada.
Mark MindenPrincess Margaret Cancer Center, Ontario Cancer Institute, 610 University Ave, Toronto, ON, M5G 2M9, Canada.
Jessica LucUniversity of Waterloo, 200 University Ave. W., Waterloo, ON, N2L 3G1, Canada.
Andrew C DoxeyUniversity of Waterloo, 200 University Ave. W., Waterloo, ON, N2L 3G1, Canada.
Paul A SpagnuoloDepartment of Food Science, University of Guelph, 50 Stone Rd., Guelph, ON, N1G2W1, Canada. paul.spagnuolo@uoguelph.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute myeloid leukemia (AML) is a devastating hematological malignancy with limited therapeutic options and poor survival outcomes. Therefore, the development of novel and selective anti-AML therapies is needed. 6-methoxydihydroavicine (6ME), a benzophenanthridine alkaloid, imparted selective AML cell death in vitro and in vivo. Mechanistically, 6ME inhibited fatty acid oxidation (FAO) by binding to and decreasing the activity of PPARδ, a transcription factor involved in FAO.

methodsAML cell lines and patient-derived cells were used to assess the activity of 6ME in vitro and in vivo. Computational methods, immunoblotting, and co-IP-HPLC analysis assessed the molecular target, and cellular consequence of 6ME activity.

results6ME induced cytotoxicity of AML cell lines (IC

conclusionPharmacological inhibition of PPARδ with 6ME is a novel approach to inducing selective death in AML.

Indexed as

6-methoxydihydroavicineAcute myeloid leukemiaFatty acid oxidationPPAR

Identifiers

PMID40713763
PMCPMC12297851

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.